NCT05389514 2025-11-20
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
Providence Health & Services
Temporarily not available
Clinical Trials
5 trialsNCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing
NCT04135092 2020-09-04
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
No longer available
NCT01005537 2010-08-06
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
No longer available